Significant knowledge gaps about biosimilars persist among consumers and healthcare professionals, hindering their adoption ...

Number 5: Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory ...

Biosimilar SB12 demonstrated comparable efficacy and safety for paroxysmal nocturnal hemoglobinuria (PNH) to its reference drug, showing similar outcomes across diverse patient groups.

Recent developments in rheumatology highlight progress in biosimilar access and use, including FDA approval of a pediatric indication for Steqeyma, setbacks and partnerships affecting adalimumab ...